NCT04720976: JAB-3312 Activity in Adult Patients With Advanced Solid Tumors

NCT04720976
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Tyrosine-Kinase Inhibitor, Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have at least 1 measurable lesion
Exclusions: Patients with brain or spinal metastases
https://ClinicalTrials.gov/show/NCT04720976

Comments are closed.

Up ↑